I've seen it in a couple of low-key (read: Non-FDA) trials, but for anything FDA-scale I think most people are wary about submitting studies that presume their subject can't possibly have -worse- results. If it's one of the early Phase 3's, it's just an unwarranted assumption, and people will be all over you for picking a more lenient study design without damn good reason to.